Previous Page  4 / 5 Next Page
Information
Show Menu
Previous Page 4 / 5 Next Page
Page Background

Note:

Journal of Diabetology | Volume 3

Page 17

July 25-26, 2019 | Amsterdam, Netherlands

OF EXCELLENCE

IN INTERNATIONAL

MEETINGS

alliedacademies.com

YEARS

Diabetes Conference 2019

3

rd

International Conference on

DIABETES, NUTRITION,

METABOLISM & MEDICARE

GLYCEMIC ACTIVITY OF CATHINONE IN TYPE 2 DIABETES-INDUCED RATS

Abdulsamad Alsalahi, Zahurin Mohamed, Zamri Chik

and

Mohammed A Alshawsh

University of Malaya, Malaysia

T

he glycemic activity of cathinone (Bioactive alkaloid of the plant Catha edulis; Khat) in non-diabetic animals

was reported, however; it’s

in vivo

glycemic activity in diabetes-induced animals has not yet been report-

ed. Therefore, the

in vitro

inhibitory effect of cathinone against α-amylase and α-glucosidase and its

in vivo

glycemic activity in diabetes-induced rats were investigated. Totally, 15 rats were fed on high-fat diet for five

weeks followed by IP-injection with 30mg/kg streptozotocin. Diabetic rats were distributed into four groups

(n=5); diabetic control (DC), 10 mg/kg glibenclamide (DG), 1.6mg/kg cathinone. Another five rats were fed on

normal diet and designed as a non-diabetic control (NC). Four weeks after treatment, rats were sacrificed to

collect blood for biochemistry and pancreas for histopathology. The

in vitro

inhibitory activity of cathinone

was significantly less potent than that of α-acarbose against α-amylase and α-glucosidase (IC50: 92.60±3.29

and 194.21±0.89µg/ml, respectively). Cathinone significantly increased fasting blood sugar, but significantly

decreased body weight and caloric intake as compared to baseline. Cathinone significantly decreased insulin

levels as compared to the DC group. In conclusion, cathinone could not exert substantial

in vitro

inhibitory

effects against α-amylase and α-glucosidase; however, it exacerbated hyperglycemia of diabetes-induced rats”.

Abdulsamad Alsalahi et al., J Diabetol 2019, Volume 3

Abdulsamad Alsalahi is about to complete his PhD from University of Malaya, Malaysia. He is a PhD student at Department of Phar-

macology, Faculty of Medicine, University of Malaya, Malaysia. He is a Lecturer at the Faculty of Pharmacy, Sana’a University, Yemen.

He has 10 publications (ISI) that have been cited 93 times, and has been serving as a reviewer of reputed BMC Complementary and

Alternative Medicine.

ahmedsamad28@yahoo.com

BIOGRAPHY